185 related articles for article (PubMed ID: 27140314)
41. Pharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice.
Grabow S; Waring P; Happo L; Cook M; Mason KD; Kelly PN; Strasser A
Cell Death Differ; 2012 Apr; 19(4):623-32. PubMed ID: 21997189
[TBL] [Abstract][Full Text] [Related]
42. Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins.
Hadjidaniel MD; Reynolds CP
Mol Cancer Ther; 2010 Dec; 9(12):3164-74. PubMed ID: 21159604
[TBL] [Abstract][Full Text] [Related]
43. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.
Del Gaizo Moore V; Schlis KD; Sallan SE; Armstrong SA; Letai A
Blood; 2008 Feb; 111(4):2300-9. PubMed ID: 18056841
[TBL] [Abstract][Full Text] [Related]
44. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
[TBL] [Abstract][Full Text] [Related]
45. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis.
Lawlor KE; Smith SD; van Nieuwenhuijze A; Huang DC; Wicks IP
J Leukoc Biol; 2011 Oct; 90(4):819-29. PubMed ID: 21719460
[TBL] [Abstract][Full Text] [Related]
47. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
[TBL] [Abstract][Full Text] [Related]
48. The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma.
Lieber J; Armeanu-Ebinger S; Fuchs J
Int J Mol Sci; 2015 Feb; 16(2):4190-208. PubMed ID: 25690034
[TBL] [Abstract][Full Text] [Related]
49. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.
Bogenberger JM; Kornblau SM; Pierceall WE; Lena R; Chow D; Shi CX; Mantei J; Ahmann G; Gonzales IM; Choudhary A; Valdez R; Camoriano J; Fauble V; Tiedemann RE; Qiu YH; Coombes KR; Cardone M; Braggio E; Yin H; Azorsa DO; Mesa RA; Stewart AK; Tibes R
Leukemia; 2014 Aug; 28(8):1657-65. PubMed ID: 24451410
[TBL] [Abstract][Full Text] [Related]
50. Targeting multiple arms of the apoptotic regulatory machinery.
Dai Y; Grant S
Cancer Res; 2007 Apr; 67(7):2908-11. PubMed ID: 17409392
[TBL] [Abstract][Full Text] [Related]
51. BH3 mimetics to improve cancer therapy; mechanisms and examples.
Zhang L; Ming L; Yu J
Drug Resist Updat; 2007 Dec; 10(6):207-17. PubMed ID: 17921043
[TBL] [Abstract][Full Text] [Related]
52. ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells.
Wang H; Yang YB; Shen HM; Gu J; Li T; Li XM
PLoS One; 2012; 7(12):e52483. PubMed ID: 23285061
[TBL] [Abstract][Full Text] [Related]
53. ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.
Traini R; Ben-Josef G; Pastrana DV; Moskatel E; Sharma AK; Antignani A; Fitzgerald DJ
Mol Cancer Ther; 2010 Jul; 9(7):2007-15. PubMed ID: 20587662
[TBL] [Abstract][Full Text] [Related]
54. Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.
Li M; Chen F; Clifton N; Sullivan DM; Dalton WS; Gabrilovich DI; Nefedova Y
Mol Cancer Ther; 2010 Dec; 9(12):3200-9. PubMed ID: 21159606
[TBL] [Abstract][Full Text] [Related]
55. Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.
Park D; Magis AT; Li R; Owonikoko TK; Sica GL; Sun SY; Ramalingam SS; Khuri FR; Curran WJ; Deng X
Cancer Res; 2013 Sep; 73(17):5485-96. PubMed ID: 23824742
[TBL] [Abstract][Full Text] [Related]
56. Resistance to BH3 mimetic S1 in SCLC cells that up-regulate and phosphorylate Bcl-2 through ERK1/2.
Liu Y; Zhang Z; Song T; Liang F; Xie M; Sheng H
Br J Pharmacol; 2013 Aug; 169(7):1612-23. PubMed ID: 23651505
[TBL] [Abstract][Full Text] [Related]
57. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737.
Jayanthan A; Howard SC; Trippett T; Horton T; Whitlock JA; Daisley L; Lewis V; Narendran A
Leuk Lymphoma; 2009 Jul; 50(7):1174-82. PubMed ID: 19557638
[TBL] [Abstract][Full Text] [Related]
58. Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells.
Hollevoet K; Antignani A; Fitzgerald DJ; Pastan I
J Immunother; 2014 Jan; 37(1):8-15. PubMed ID: 24316551
[TBL] [Abstract][Full Text] [Related]
59. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Jóna A; Khaskhely N; Buglio D; Shafer JA; Derenzini E; Bollard CM; Medeiros LJ; Illés A; Ji Y; Younes A
Exp Hematol; 2011 Oct; 39(10):1007-1017.e1. PubMed ID: 21767511
[TBL] [Abstract][Full Text] [Related]
60. An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
Oltersdorf T; Elmore SW; Shoemaker AR; Armstrong RC; Augeri DJ; Belli BA; Bruncko M; Deckwerth TL; Dinges J; Hajduk PJ; Joseph MK; Kitada S; Korsmeyer SJ; Kunzer AR; Letai A; Li C; Mitten MJ; Nettesheim DG; Ng S; Nimmer PM; O'Connor JM; Oleksijew A; Petros AM; Reed JC; Shen W; Tahir SK; Thompson CB; Tomaselli KJ; Wang B; Wendt MD; Zhang H; Fesik SW; Rosenberg SH
Nature; 2005 Jun; 435(7042):677-81. PubMed ID: 15902208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
